Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprocitentan in uncontrolled blood pressure with chronic kidney disease stage 3 or 4
2018-003819-22Phase 3Terminated
- Sponsor
- Idorsia
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aprocitentan in hypertension (HTN) (2 arms), sponsored by Idorsia. Primary endpoint: Change in mean trough sitting systolic blood pressure at Week 4. Started Sep 2019; status: terminated.
02
Drugs
aprocitentan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2018-003819-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003819-22.